Century Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 14, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 14, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| CENTURY THERAPEUTICS, INC. | |
| By: | /s/ Brent Pfeiffenberger, PharmD, MBA |
| Brent Pfeiffenberger, PharmD, MBA | |
| Chief Executive Officer |
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date | ||
|---|---|---|---|---|
| /s/ Brent Pfeiffenberger, PharmD, MBA | Chief Executive Officer and Director (principal executive officer) | March 14, 2024 | ||
| Brent Pfeiffenberger, PharmD, MBA | ||||
| Interim Principal Financial Officer(principal financial officer and principal accounting officer) | March 14, 2024 | |||
| /s/ Douglas Carr | | | ||
| Douglas Carr | | | ||
| | | | | |
| /s/ Kimberly Blackwell, M.D. | Director | March 14, 2024 | ||
| Kimberly Blackwell, M.D. | ||||
| | | | | |
| /s/ Cynthia Butitta | Director | March 14, 2024 | ||
| Cynthia Butitta | ||||
| | | | | |
| /s/ Joseph Jimenez | Director, Chairman of the Board | March 14, 2024 | ||
| Joseph Jimenez | ||||
| | | | | |
| /s/ Alessandro Riva, M.D. | Director | March 14, 2024 | ||
| Alessandro Riva, M.D. | ||||
| | | | | |
| /s/ Carlo Rizzuto, Ph.D. | Director | March 14, 2024 | ||
| Carlo Rizzuto, Ph.D. | ||||
| | | | | |
| /s/ Timothy Walbert | | Director | | March 14, 2024 |
| Timothy Walbert | | | ||
| | | | | |
| /s/ Daphne Quimi | | Director | | March 14, 2024 |
| Daphne Quimi | | | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.